arrow
B

Benoît Tessoulin

university hospital of nantes
H指数:30
被引数:3,186

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Proton pump inhibitors and outcome after axicabtagene ciloleucel for the treatment of non-Hodgkin B-cell lymphoma, a retrospective study with the DESCAR-T registry

质子泵抑制剂及在非霍奇金B细胞淋巴瘤的axicabtagene ciloleucel治疗后的结局:一项基于DESCAR-T登记研究的回顾性研究

2026-11-060
OAAI
Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

BRUIN 1/2 期研究的最终分析:评估吡鲁托布替尼单药治疗 <scp>MCL</scp> 患者的安全性和有效性

2026-11-040
OAAI
B-Cell Maturation Antigen T-Cell Engager Therapy in a Patient With Refractory Plasma Cell Clonal Cryoglobulinemia Unmasked by RNA-Based Immunoglobulin Sequencing

B细胞成熟抗原T细胞衔接疗法在一名经RNA基免疫球蛋白测序确诊的难治性浆细胞克隆性冷球蛋白血症患者中的应用

2026-11-030
PRE
End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

诱导治疗结束时的循环肿瘤DNA优于常规细胞微小残留病,用于预测滤泡性淋巴瘤的早期进展:RELEVANCE随机试验的辅助研究

2026-09-290
OAAI
Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort

套细胞淋巴瘤的现代治疗与生存结局:来自REALYSA(LYSA队列)的国家真实世界分析

2026-09-220
OAAI
Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era

REALYSA队列研究中预CAR T时代一线治疗后难治性和早期复发性大B细胞淋巴瘤患者的结局

2026-09-060
OAAI
Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study

CAR T细胞疗法期间复发/难治性弥漫大B细胞淋巴瘤的标准化FDG-PET解读:一项DESCAR-T研究

2026-07-250
PRE
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group

二线CAR T细胞治疗后进展的大B细胞淋巴瘤的结局和挽救策略:LYSA小组的DESCAR-T研究

2026-05-060
OAAI
CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival

CD40/PI3K/FOXO1轴的重编程驱动微环境依赖性的BIM沉默,以维持淋巴瘤的生长和存活。

Leukemia
IF13.4
2026-02-190
PRE
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study

Pirtobrutinib,R/R边缘区淋巴瘤中的高选择性,非共价 (可逆) BTKi: 1/2期布鲁因研究

2026-01-200
OAAI
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials

基于LYSA组混合临床试验和真实世界数据的老年(>80岁)未治弥漫性大B细胞淋巴瘤患者的合成对照臂:一种创新临床试验的真实可行策略

2025-11-030
OAAI
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

CAR T细胞疗法后侵袭性B细胞淋巴瘤的晚期复发:一项来自DESCAR-T登记研究的LYSA研究

2025-10-240
OAAI
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group

抗CD19 CAR-T细胞疗法失败后套细胞淋巴瘤患者的结局:Descar-T研究(Lysa集团)

2025-10-030
OAAI